Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement
June 08, 2020 08:05 ET
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., June 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Receives Extension From Nasdaq to Satisfy Continuing Listing Requirements
June 04, 2020 16:05 ET
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., June 04, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Announces Results of 2020 Annual Meeting of Shareholders
May 15, 2020 16:45 ET
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., May 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Announces Virtual 2020 Annual Meeting of Shareholders
May 08, 2020 09:00 ET
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., May 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Reports First Quarter 2020 Financial and Operating Results
May 06, 2020 08:05 ET
|
Aeterna Zentaris Inc.
– First quarter marked by positive results from AEZS-130-P01 (“Study P01”), of macimorelin, providing clinical framework to advance pediatric investigation plan (“PIP”) for macimorelin as a growth...
Aeterna Zentaris Receives Nasdaq Notice of Non-Compliance; No Immediate Impact on Listing
April 15, 2020 16:06 ET
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Zentaris to Present at the April 2020 Virtual Investor Summit
April 15, 2020 09:15 ET
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and...
AETERNA ZENTARIS ANNOUNCES EMA DECISION TO ACCEPT A MODIFICATION TO AN AGREED PEDIATRIC INVESTIGATION PLAN FOR MACIMORELIN
April 07, 2020 13:00 ET
|
Aeterna Zentaris Inc.
– Modifications recommended for some key elements of planned safety and efficacy Study P02 – – Modifications to the outline of Study P02 requested to ensure a harmonized global study protocol...
AETERNA ZENTARIS ANNOUNCES POSITIVE RESULTS IN DOSE-FINDING PEDIATRIC STUDY OF MACIMORELIN
April 06, 2020 09:00 ET
|
Aeterna Zentaris Inc.
– Positive results provide clinical framework to advance the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic – – Pediatric PK/PD profile of...
AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE
March 30, 2020 17:00 ET
|
Aeterna Zentaris Inc.
– Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ – – Robust ongoing business development discussions to secure a...